key: cord-0685549-s5l593ox
authors: Anand, Sai Priya; Prévost, Jérémie; Nayrac, Manon; Beaudoin-Bussières, Guillaume; Benlarbi, Mehdi; Gasser, Romain; Brassard, Nathalie; Laumaea, Annemarie; Gong, Shang Yu; Bourassa, Catherine; Brunet-Ratnasingham, Elsa; Medjahed, Halima; Gendron-Lepage, Gabrielle; Goyette, Guillaume; Gokool, Laurie; Morrisseau, Chantal; Bégin, Philippe; Martel-Laferrière, Valérie; Tremblay, Cécile; Richard, Jonathan; Bazin, Renée; Duerr, Ralf; Kaufmann, Daniel E.; Finzi, Andrés
title: Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months post-symptom onset
date: 2021-05-05
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2021.100290
sha: b6a8c7399a4adaa278b43cd0dfe6549b0949f8ad
doc_id: 685549
cord_uid: s5l593ox

With the recent approval of highly effective COVID-19 vaccines, functional and lasting immunity to SARS-CoV-2 is currently under investigation as antibody levels in plasma were shown to decline during convalescence. Since the absence of antibodies does not equate to absence of immune memory, we evaluate the presence of SARS-CoV-2-specific memory B cells in convalescent individuals. Here we report a longitudinal assessment of humoral immune responses on 32 donors up to 8 months post-symptom onset. Our observations indicate that anti-Spike and anti-RBD IgM in plasma decay rapidly, whereas the reduction of IgG is less prominent. Neutralizing activity also declines rapidly when compared to Fc-effector functions. Concomitantly, the frequencies of RBD-specific IgM+ B cells wane significantly when compared to RBD-specific IgG+ B cells which remain stable. Our results add to the current understanding of immune memory following SARS-CoV-2 infection, which is critical for the prevention of secondary infections and vaccine efficacy.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of the 51 ongoing Coronavirus disease 2019 (COVID-19) pandemic, is highly contagious and has infected 52 close to a 100 million people worldwide and caused over 2 million deaths since its discovery. 53

The dynamics and persistence of immune responses in individuals infected with SARS-CoV-2 is 54 currently under needful investigation. Several studies with acute and convalescent COVID-19 55 patients have showed prompt induction of B and T cell responses upon infection, along with the 56 detection of antigen-specific memory B and T cell responses several weeks into convalescence 57 [1] [2] [3] [4] [5] [6] . Additionally, antibodies induced upon infection have been shown to protect from SARS-CoV-58 2 reinfection in animal models [7] [8] [9] . Passive immunization using neutralizing monoclonal antibody 59 treatments decreased viral loads in animal studies and in patients with 11 . The viral 60 target of neutralizing antibodies is the highly immunogenic trimeric Spike (S) glycoprotein, which 61 facilitates SARS-CoV-2 entry into host cells via its receptor-binding domain (RBD) that interacts 62 with angiotensin-converting enzyme 2 (ACE-2) 12, 13 . 63

The evolution of overall antibody responses in convalescent individuals is being extensively 65 analysed, with studies showing that Ab titers and neutralization activity against Spike start 66 decreasing during the first weeks after resolution of infection 3, 6, [14] [15] [16] [17] [18] [19] [20] . Importantly, in addition to 67 neutralizing viral particles, the antiviral activities of SARS-CoV-2-specific antibodies can expand 68 to involve Fc-effector functions, including antibody-dependent cellular cytotoxicity (ADCC) 21, 22 . To monitor the evolution of antibody responses longitudinally, we analyzed serological samples 83 from 32 convalescent individuals (Table 1) Convalescent participants were enrolled following two negative RT-PCR tests and a complete 92 resolution of symptoms for at least 14 days before blood sampling. 93

We began by evaluating the presence of RBD-specific IgG, IgM, and IgA antibodies by using a 95 previously published enzyme-linked immunosorbent assay (ELISA) against the SARS-CoV-2 96 RBD antigen 16 . In agreement with recent reports showing the waning of antibody levels in 97 longitudinal convalescent plasma over time 14-17 , we observed that total RBD-specific 98 immunoglobulin (Ig) levels, comprising of IgG, IgM, and IgA, gradually decreased between 6 99 and 31 weeks after the onset of symptoms ( Figure 1A) . However, the percentage of 100 convalescent individuals presenting detectable RBD-specific Ig levels remained stable, with a 101 J o u r n a l P r e -p r o o f consistent seropositivity rate above 90% throughout the sampling time frame. Notably, 100% of 102   the donors still had detectable IgG at the last time point, while IgM and IgA diminished more  103 rapidly, with 85% and 69% of the donors having undetectable IgM and IgA levels, respectively, 104 31 weeks PSO (Figure 1B-D; Figure S1A ). Since the RBD ELISA is limited to detect antibodies 105 targeting only one domain of the Spike, we developed a high-throughput cell-based ELISA 106 methodology to screen for antibodies recognizing the native full-length S protein on the cell 107 surface. HOS cells stably expressing the SARS-CoV-2 S glycoproteins were incubated with 108 plasma samples, followed by the addition of secondary antibodies recognizing IgG, IgM, and/or 109 IgA. We observed that 100% of the donors still had detectable S-specific total Ig and IgG in their 110 plasma at 31 weeks PSO whereas, only 38% and 54% of the plasma samples tested positive 111

for the presence of Spike-specific IgM and IgA, respectively (Figure 1 E-H; Figure S1B ). We Recent studies have shown the importance of neutralizing antibodies in reducing viral load and 120 preventing infection in animal models 10, 25, 26 . Neutralizing monoclonal antibody cocktails also 121 reduced viral load in COVID-19 patients 11 . Neutralizing activity is often considered as a 122 determining factor in convalescent plasma therapy, although its relative importance compared to 123

Fc-effector activity is still unknown [27] [28] [29] . Thus, we measured the capacity of convalescent 124 plasma to neutralize pseudoviral particles carrying the SARS-CoV-2 Spike protein over time. Neutralizing antibody titers (ID 50 ) were detected in 63% of the donors at 6 weeks PSO, while 126 none of the uninfected controls had detectable neutralizing activity. Titers declined from 155.6 at 127 J o u r n a l P r e -p r o o f 6 weeks to 60.0 at 31 weeks PSO, respectively, with 77% of donors having undetectable 128 neutralization activity in their plasma at the last time point (Figure 2A ). Of note, plasma from 129 individuals that had undetectable neutralization activity at later time points, started with lower 130 peak titers at earlier time points. Since the depletion of IgM from plasma has been associated 131 with loss of viral neutralization capacity 30,31 and IgA has also been shown to dominate the early 132 neutralizing response 32,33 , the sharp decline in neutralization activity seen in this study is 133 corroborated by the striking decrease in anti-Spike and anti-RBD IgM and IgA levels ( Figure 1B We developed an ADCC assay using a human T-lymphoid cell line resistant to NK cell-mediated 142 cell lysis (CEM.NKr) and stably expressing the full-length S protein on the cell surface as target 143 cells. PBMCs from healthy individuals were used as effector cells. ADCC activity was measured 144 by the loss of Spike-expressing GFP+ target cells ( Figure S3 ). We observed that ADCC activity 145 of convalescent plasma decreased gradually between 6 weeks and 31 weeks PSO ( Figure 2B ). 146

However, this decline was modest when compared to the decrease in neutralization activity of 147 plasma ( Figure S1C ) and 85% of the donors' plasma still elicited substantial ADCC activity at 148 the latest study time point. As expected, the levels of ADCC activity strongly correlated with the 149 levels of anti-Spike IgG ( Figure S5 ). The presence of Fc-mediated antibody effector functions up 150 to 8 months PSO is corroborated with the presence of significant IgG levels. was not detected in PBMCs from uninfected individuals ( Figure S4A , B). RBD-specific B cells 163 were detected 6 weeks PSO with a modest increase in mean frequency up to 31 weeks PSO 164 (0.038% to 0.051%) ( Figure 3B ). Total RBD-specific B cells were evaluated to distinguish 165

surface Ig isotypes and we observed IgG+, IgM+ and IgA+ cells in 100%, 92% and 83% of 166 donors at 6 weeks PSO, respectively. Strikingly, the frequency of RBD-specific IgM+ B cells 167 decreased significantly, with 46% of the donors having undetectable IgM+ B cells 31 weeks 168 PSO ( Figure 3C ; Figure S1D ). Conversely, the frequency of RBD-specific IgG+ B cells 169 significantly increased between 6 and 21 weeks PSO and remained stable up to 8 months PSO 170 ( Figure 3D ); the detection of RBD-specific IgA+ B cells also persisted in 77% of the donors 171 tested ( Figure 3E ; Figure S1D ). Furthermore, the total RBD-specific B cells were evaluated to 172 distinguish memory and naïve B cells (identified by using CD27 and CD21 markers; Figure S4C , 173 D). Importantly, total RBD-specific memory B cells were detected in 100% of the donors and the 174 mean frequency remained stable between 6 and 31 weeks PSO (0.020% to 0.026%), while 175 RBD-specific naïve B cells were observed in lower proportions and modestly decreased over 176 time ( Figure 3F , G). Interestingly, the proportion of donors positive for RBD-specific naïve B 

A limitation of the current study is the relatively low number of individuals studied, which can 254 affect the power of our statistical analyses. Longitudinal data from a larger sample size with 255 varying clinical symptoms ranging from asymptomatic to critical cases as well as individuals 256 below 20 years and over 65 years of age would be required for a more precise understanding of 257 the overall immune durability against COVID-19. However, we note that results as obtained in 258 this study are very similar to those observed in larger cross-sectional and longitudinal studies 259 3,5,6 . 260 SEM. Statistical significance was tested using repeated measures one-way ANOVA with a 322

Holm-Sidak post-test (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001). 

The present study aims to determine the kinetics of the humoral response following SARS-CoV-402 2 infection. All available samples from adults recovered from SARS-CoV-2 infection collected at 403 the time of the study were analyzed. No specific criteria such as number of patients (sample 404 size), clinical or demographic were used for inclusion, beyond PCR confirmed SARS-CoV-2 405 infection in adults. A summary of demographic parameters for all individuals is included in Table  406 1. While all the participants were symptomatic at the time of the infection, none of them were 407 hospitalized. The disease severity ranged from mild to moderate symptoms without any severe 408 or critical cases. 

Plasma from SARS-CoV-2-infected and pre-pandemic uninfected donors were collected, heat-429 inactivated for 1h at 56°C and stored at -80°C until ready to use in subsequent experiments. 430

Plasma from uninfected donors were used as negative controls and used to calculate the 431 seropositivity threshold in our ELISA, cell-based ELISA, and flow cytometry assays. The RBD-432 specific monoclonal antibody CR3022 46 was used as a positive control in our ELISAs, cell-433 based ELISAs, and flow cytometry assays and was previously described 14, 16, 24 

FreeStyle 293F cells (Thermo Fisher Scientific ) were grown in FreeStyle 293F medium 445 (Thermo Fisher Scientific ) to a density of 1 x 10 6 cells/mL at 37°C with 8% CO 2 with regular 446 agitation (150 rpm). Cells were transfected with a plasmid coding for SARS-CoV-2 S RBD using 447

ExpiFectamine 293 transfection reagent, as directed by the manufacturer (Thermo Fisher 448 Scientific ). One week later, cells were pelleted and discarded. Supernatants were filtered using 449 a 0.22 µm filter (Thermo Fisher Scientific). The recombinant RBD proteins were purified by 450 nickel affinity columns, as directed by the manufacturer (Invitrogen). The RBD preparations 451 were dialyzed against phosphate-buffered saline (PBS) and stored in aliquots at -80°C until 452 further use. To assess purity, recombinant proteins were loaded on SDS-PAGE gels and 453 stained with Coomassie Blue. 454

The SARS-CoV-2 RBD ELISA assay used was recently described 16 were mixed at a ratio of 1:10 in 96-well V-bottom plates. Plasma from COVID+ or COVID-512 individuals (1/500 dilution) or monoclonal antibody CR3022 (1 µg/mL) were added to the 513 appropriate wells. The plates were subsequently centrifuged for 1 min at 300xg, and incubated 514 at 37°C, 5% CO 2 for 5 hours before being fixed in a 2% PBS-formaldehyde solution. ADCC 515 activity was calculated using the formula: [(% of GFP+ cells in Targets plus Effectors)-(% of 516

by gating on transduced live target cells. All samples were acquired on an LSRII cytometer (BD 518 Biosciences) and data analysis performed using FlowJo v10.7.1 (Tree Star). The specificity 519 threshold was established using the following formula: mean of all COVID-19 negative plasma + 520 1h at 37°C and were then added to the target cells followed by incubation for 48h at 37°C; cells 532 were lysed by the addition of 30 µL of passive lysis buffer (Promega) followed by one freeze-533 thaw cycle. An LB942 TriStar luminometer (Berthold Technologies) was used to measure the 534 luciferase activity of each well after the addition of 100 µL of luciferin buffer (15mM MgSO 4 , 535

15mM KPO 4 [pH 7.8], 1mM ATP, and 1mM dithiothreitol) and 50 µL of 1mM d-luciferin 536 potassium salt (Thermo Fisher Scientific). The neutralization half-maximal inhibitory dilution 537 (ID 50 ) represents the plasma dilution to inhibit 50% of the infection of 293T-ACE2 cells by 538 SARS-CoV-2 pseudoviruses. 539 540

To detect SARS-CoV-2-specific B cells, we conjugated recombinant RBD proteins with Alexa 542

Fluor 488 or Alexa Fluor 594 (Thermo Fisher Scientific) according to the manufacturer's 543 protocol. Approximately 10 x 10 6 frozen PBMC from 13 convalescent donors were prepared in 544

Falcon® 5ml-round bottom polystyrene tubes at a final concentration of 14 x 10 6 cells/mL in 545 RPMI 1640 medium (Gibco) supplemented with 10% of fetal bovine serum (Seradigm), 546

Penicillin-Streptomycin (Gibco) and HEPES (Gibco ). After a rest of 2h at 37°C and 5% CO 2 , 547 cells were stained using Aquavivid viability marker (Gibco) in DPBS (Gibco) at 4°C for 20min. 548

The detection of SARS-CoV-2-antigen specific B cells was done by adding the RBD probes to 549 the following antibody cocktail: IgM BUV737, CD24 BUV805, IgG BV421, CD3 BV480, CD56 550 BV480, CD14 BV480 , CD16 BV480, CD20 BV711, CD21 BV786, HLA DR BB700 , CD27 APC 551 R700 all from BD Biosciences; CD19 BV650 from Biolegend and IgA PE from Miltenyi. Staining 552 was performed at 4°C for 30min and cells were fixed using 2% paraformaldehyde at 4°C for 553 15min. Stained PBMC samples were acquired on Symphony cytometer (BD Biosciences) and 554 analyzed using FlowJo v10.7.1 (TreeStar). In each experiment, PBMC from unexposed donors 555 (total of n=9) were included to ensure consistent specificity of the assay. 

Statistics were analyzed using GraphPad Prism version 9.0.0 (GraphPad, San Diego, CA). 560

Every dataset was tested for statistical normality and this information was used to apply the 561 appropriate (parametric or nonparametric) statistical test. P values < 0.05 were considered 562 significant; significance values are indicated as * p < 0.05, * * p < 0.01, * * * p < 0.001, * * * * p < 563 0.0001. Multiplicity adjustments of p values were performed with the Benjamini-Hochberg 564 method in R and R Studio 47,48 using the data.table and tidyverse packages. 565 566

Normalized heatmaps were generated using the complexheatmap, tidyverse, and viridis 568 packages in R and RStudio 47,48 . Normalizations were done per parameter. IDs were grouped 569 and clustered separately according to time point. Correlograms were generated using the 570 corrplot and RColorBrewer packages in program R and RStudio using hierarchical clustering 571 according to the first principal component (FPC). Circular barplots were generated in R and 572

RStudio using the tidyverse package with averaged, normalized data per parameter and time 573 point. Edge bundling graphs were generated in undirected mode in R and RStudio using 574 ggraph, igraph, tidyverse, and RColorBrewer packages. Edges are only shown if p < 0.05, and 575 nodes are sized according to the connecting edges' r values. Nodes are color-coded according 576 to groups of parameters. Area graphs were generated for the display of normalized time series. 577

The plots were created in RawGraphs using DensityDesign interpolation and vertically un- 

Antigen-Specific Adaptive 584 Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease 585 Severity

Rapid generation of 588 durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 589 and convalescence

Evolution of antibody 592 immunity to SARS-CoV-2

Targets of T Cell 595 Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease

Immunological memory to SARS-CoV-2 599 assessed for up to 8 months after infection

Evolution of immune responses 602 to SARS-CoV-2 in mild-moderate COVID-19

SARS-CoV-2 infection 606 protects against rechallenge in rhesus macaques

Correlates of protection against SARS-610

CoV-2 in rhesus macaques

Ultrapotent human 613 antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

REGN-COV2 antibodies prevent and treat 617 SARS-CoV-2 infection in rhesus macaques and hamsters

REGN-COV2, a Neutralizing Antibody

Outpatients with Covid-19

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

SARS-CoV-2 Cell 627 Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease 628 Inhibitor

Decline of Humoral 631

Responses against SARS-CoV-2 Spike in Convalescent Individuals

Waning of SARS-CoV-2 RBD 635 antibodies in longitudinal convalescent plasma samples within four months after 636 symptom onset

Cross-sectional evaluation 639 of humoral responses against SARS-CoV-2 Spike

Convergent antibody 643 responses to SARS-CoV-2 in convalescent individuals

Rapid Decay 647 of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Longitudinal observation and 651 decline of neutralizing antibody responses in the three months following SARS-CoV-2 652 infection in humans

Stable neutralizing antibody levels 6 months after mild and severe COVID-656 19 episodes

The Fc-mediated effector 659 functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early 660 convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the 661 antibody

Asymptomatic and 664 symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies

Compromised Humoral Functional Evolution 668 Tracks with SARS-CoV-2 Mortality

High-throughput detection of antibodies 672 targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples. 673 Transfusion

Studies in humanized mice and convalescent 676 humans yield a SARS-CoV-2 antibody cocktail

Isolation of potent SARS-CoV-2 neutralizing 680 antibodies and protection from disease in a small animal model

Convalescent plasma in Covid-19: Possible mechanisms of action

Effect of Convalescent Plasma Therapy on Time to Clinical 688 Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized 689 Clinical Trial

Efficacy and safety of convalescent plasma for severe 692 COVID-19 based on evidence in other severe respiratory viral infections: a systematic 693 review and meta-analysis

Role of IgM and IgA Antibodies in 696 the Neutralization of SARS-CoV-2

Major role of IgM in the neutralizing 699 activity of convalescent plasma against SARS-CoV-2

IgA dominates the early neutralizing antibody 703 response to SARS-CoV-2

Enhanced SARS-CoV-2 706 neutralization by dimeric IgA

Antibody 709 potency, effector function, and combinations in protection and therapy for SARS-CoV-2 710 infection in vivo

Presence of antibody-713 dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma

Cross-reactive serum and memory B cell 717 responses to spike protein in SARS-CoV-2 and endemic coronavirus infection

Disease severity dictates SARS-CoV-2-specific neutralizing antibody 721 responses in COVID-19

A 725 systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates 726 of protection, and association with severity

CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 731 weeks

SARS-CoV-2 antibody 734 signatures robustly predict diverse antiviral functions relevant for convalescent plasma 735 therapy

mRNA vaccine-738 elicited antibodies to SARS-CoV-2 and circulating variants

Live imaging of SARS-CoV-2 742 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy

Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an 747 early predictor of COVID-19 mortality

The interferon-inducible MxB protein inhibits HIV-1 infection

The membrane-proximal 753 intracytoplasmic tyrosine residue of HIV-1 envelope glycoprotein is critical for basolateral 754 targeting of viral budding in MDCK cells

Human 757 monoclonal antibody combination against SARS coronavirus: synergy and coverage of 758 escape mutants

RStudio: Integrated Development for R

R: A language and environment for statistical 761 computing (R Foundation for Statistical Computing)

RAWGraphs: A 763 Visualisation Platform to Create Open Outputs